Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026
Same author

Inhibition of PRMT5 sensitizes B-cell non-Hodgkin lymphoma cells to both intrinsic and extrinsic apoptotic cell death.

Blood neoplasia·2026
Same author

SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLL.

Blood advances·2026
Same author

A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Publisher Correction: Single-cell epigenetic and transcriptomic states across the continuum of monoclonal B cell lymphocytosis to chronic lymphocytic leukemia.

Genome biology·2026
Same author

Single-cell epigenetic and transcriptomic states across the continuum of monoclonal B cell lymphocytosis to chronic lymphocytic leukemia.

Genome biology·2026

Related Experiment Video

Updated: Mar 1, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.6K

IGHV mutational status testing in chronic lymphocytic leukemia.

Jennifer Crombie1, Matthew S Davids1

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

American Journal of Hematology
|June 8, 2017
PubMed
Summary

Understanding immunoglobulin heavy chain (IGHV) gene mutational status is crucial for predicting chronic lymphocytic leukemia (CLL) treatment response and survival. This guide details IGHV testing interpretation for optimal patient care.

More Related Videos

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.4K
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.9K

Related Experiment Videos

Last Updated: Mar 1, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.6K
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

27.4K
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.9K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • The therapeutic landscape for chronic lymphocytic leukemia (CLL) is rapidly evolving.
  • Identifying reliable biomarkers for treatment response is essential for personalized medicine.
  • Immunoglobulin heavy chain (IGHV) gene mutational status is a key prognostic factor in CLL.

Purpose of the Study:

  • To elucidate the significance of IGHV mutational status as a predictive biomarker in CLL.
  • To provide a comprehensive overview of IGHV mutational status testing methodologies.
  • To guide healthcare providers in interpreting and applying IGHV test results for patient management.

Main Methods:

  • Review of current literature and clinical guidelines on IGHV mutational status testing.
  • Detailed description of the molecular techniques used for IGHV gene analysis.
  • Explanation of the criteria for classifying IGHV status as mutated or unmutated.

Main Results:

  • IGHV mutational status significantly impacts treatment decisions and patient outcomes in CLL.
  • Mutated IGHV is associated with a more indolent disease course and better response to chemoimmunotherapy (CIT).
  • Unmutated IGHV often predicts a more aggressive disease and may favor novel targeted agents.

Conclusions:

  • Accurate determination and interpretation of IGHV mutational status are critical for selecting appropriate therapies in CLL.
  • Understanding IGHV testing limitations ensures optimal application in clinical practice.
  • This biomarker empowers clinicians to tailor treatment strategies for improved patient survival and response duration.